Cardiac AI: Top FDA Clearances & Why They Matter for Investors

The diagnostic cardiac AI field is exploding, fired up by new tech and a serious need for better, more scalable heart care. If you’re an investor, analyst, or clinical evaluator trying to sort through this mess, you have to understand the regulatory story behind competing platforms. The number and type of FDA clearances a company has is a direct proxy for its clinical validation, market readiness, and, let’s be honest, whether it’s going to be a viable business.

The FDA 510(k) Pathway: A Benchmark for Diagnostic Cardiac AI

For most cardiac AI products, especially Software as a Medical Device (SaMD), the FDA 510(k) pathway is the main road to the U.S. market. The whole point of this process is to show your product is “substantially equivalent” to a device that’s already legally on the market, which makes for a simpler, though still quite rigorous, path to getting cleared for safety and effectiveness. Sure, a company might try for a De Novo classification if it has a truly new AI function with no existing predicate, but for the vast majority of diagnostic AI using ECG or auscultation data, the 510(k) is where the action is. When a single platform racks up a high number of cleared indications, that’s a huge competitive advantage. It shows they have a real system for cardiac disease detection, not just a one-off algorithm.

AliveCor’s KAI 12L: A Broad Spectrum of ECG Determinations

AliveCor’s strategy was clearly to go for a massive, single FDA clearance, and they pulled it off with their KAI 12L platform. As of January 2026, KAI 12L got an FDA clearance that covers a stunning 39 different cardiac determinations, all in one go BioSpace article announcing AliveCor KAI 12L clearance. This one event instantly makes KAI 12L a major force in the cardiac AI diagnostics market. The sheer range of these determinations, which includes all sorts of arrhythmias and other conditions you can find on a 12-lead ECG, shows they’re serious about pushing AI’s diagnostic power. From an investor’s perspective, a single, wide-ranging clearance like this is gold because it de-risks the technology across dozens of uses, which expands the addressable market and opens up more ways to make money. For a hospital, being able to buy one AI solution that handles 39 distinct cardiac findings makes integration much easier and could speed up adoption since they don’t have to manage a bunch of separate point solutions.

Eko Health’s SENSORA Platform: Modular Expansion and Foundational Models

Eko Health took a totally different route with its SENSORA platform. Instead of going for one big clearance like AliveCor, they’ve been building their regulatory portfolio piece by piece with multiple, separate FDA clearances for specific capabilities. It all started back in 2022 when they got clearance for murmur analysis, a key tool for catching valvular heart disease early Eko Health press release on murmur analysis clearance. Since then, Eko has added more clearances for AFib detection and its low ejection fraction (low-EF) algorithm, systematically growing what SENSORA can do. The most interesting move, though, was the clearance of their EFAST foundation model in September 2025. This isn’t just another algorithm, it’s a base AI architecture that can support a whole family of diagnostic apps, which suggests Eko’s plan is to deploy new AI capabilities much more quickly in the future, possibly using a Predetermined Change Control Plan (PCCP) to manage updates. While this step-by-step clearance strategy might seem slower, it’s a smart way to de-risk each individual diagnostic claim and adapt as clinical needs change, and it’s a perfect example of how AI-native companies are building out powerful, extensible platforms.

Comparative Regulatory Depth: AliveCor vs. Eko Health

If you’re just looking at the breadth of FDA clearances for diagnostic cardiac AI (the stuff based on ECG and auscultation), AliveCor and Eko Health are the two companies that matter most. AliveCor’s KAI 12L, with its 39 cleared determinations from January 2026, makes a strong argument for regulatory efficiency by getting a huge, wide-ranging product to market in a single submission. That’s a real advantage for market penetration, offering a complete package instead of a box of parts. On the other side, Eko Health’s SENSORA platform, with its collection of separately-cleared algorithms like EMAS for murmurs, AFib, low-EF, and now the EFAST foundation model, proves there’s another way to win. This approach allows for very focused development and validation, which can get individual money-making algorithms to market faster. The EFAST model in particular shows Eko is thinking big about building a scalable AI infrastructure. So what should investors make of this? It’s critical to see these as two distinct strategies. AliveCor is pursuing a “land and expand” model with a big initial offering. Eko is running a “build and layer” playbook, adding capabilities to its core platform. Both have their merits. Long-term success will come down to who doctors actually use, how reimbursement shakes out, and how quickly hospitals adopt the tech. This analysis is focused just on diagnostic cardiac AI. Other parts of the field, like preventive cardiac AI, have entirely different regulatory paths and business models. For a deeper look into preventive platforms, you should check out our other coverage on cardiacai.net.